FierceBiotech 24 abr 2026 After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?
FierceBiotech 22 abr 2026 Lilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitors
FierceBiotech 7 abr 2026 Lilly pays AC Immune $12.5M to expand Alzheimer’s collab as asset draws closer to clinic
FierceBiotech 31 mar 2026 Lilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience play
FierceBiotech 23 mar 2026 Apogee eczema data drive hype to new peak as threat to Lilly and Sanofi becomes clear
FierceBiotech 19 mar 2026 Lilly's obesity discovery partner Fauna sees weight loss potential in hibernating mammals
FierceBiotech 19 mar 2026 Lilly's triple-G bet lowers blood sugar, prompts 16.8% weight loss in phase 3 diabetes trial
FierceBiotech 9 feb 2026 Lilly, Innovent pen $8.8B oncology, immunology collab that 'moves beyond traditional licensing'
FierceBiotech 4 feb 2026 Lilly drops 3 pipeline drugs, including gene therapy, from $1B Prevail buyout
FierceBiotech 29 ene 2026 Repertoire adds Lilly to range of Big Pharma partners in autoimmune deal worth up to $2.69B
FierceBiotech 28 ene 2026 Lilly pens $1.1B pact with German biotech to work on gene editing med for hearing loss
FierceBiotech 12 ene 2026 JPM26, Day 1: Stock market titans Lilly, Nvidia expand team-up with AI co-innovation lab
FierceBiotech 12 ene 2026 Lilly, Nvidia tag on partnership with new AI co-innovation lab, $1B investment
FierceBiotech 8 ene 2026 Lilly links up with InduPro in next-gen cancer treatment deal worth up to $950M
FierceBiotech 11 dic 2025 Lilly's obesity triple threat smashes efficacy expectations in phase 3 but proves intolerable for some
FierceBiotech 8 dic 2025 With weight loss windfall, Lilly looks to become ‘backbone’ of global innovation: exec